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INTRODUCTION  
A pharmaceutical nanosuspension is defined as very 
finely dispersed solid drug particles in an aqueous 
vehicle for either oral and topical use or parenteral and 
pulmonary administration. The particle size 
distribution of the solid particles in nanosuspension is 
between 200 and 600 nm 
1
. Nanosuspension differs 
from nanoparticles. Nanoparticles are commonly 
polymeric colloidal carriers of drugs whereas solid 
lipid nanoparticles are lipid carriers of drugs. In 
nanosuspension technology, the drug is maintained in 
the required crystalline state with reduced particle size, 
leading to an increased dissolution rate and improved 
bioavailability. An increase in the dissolution rate of 
micronized particles (particle size < 10 μm) is related 
to an increase in the surface area and consequently the 
dissolution velocity. Nanosized particles can increase 
solution velocity and saturation solubility because of 
the vapor pressure effect. In addition, the diffusional 
distance on the surface of drug nanoparticles is 
decreased, thus leading to an increased concentration 
gradient. The increases in surface area and 
concentration gradient lead to a much more 
pronounced increase in the dissolution velocity as 
compared to a micronized product. Another possible 
explanation for the increased saturation solubility is the 
creation of high energy surfaces when disrupting the 
more or less ideal drug microcrystals to nanoparticles. 
The absence of particles with large differences in their 
size in nanosuspension prevents the existence of 
different saturation solubility and concentration 
gradients, consequently preventing the Oswald 
ripening effect 
2,3
. Ostwald ripening is responsible for 
crystal growth and subsequently formation of 
microparticles. It is caused by a difference in 
dissolution pressure/saturation solubility between 
small and large particles. Molecules diffuse from the 
higher concentration area around small particles which 
have higher saturation solubility to an area around 
larger particles possessing a lower drug concentration. 
This leads to the formation of a supersaturated solution 
around the large particles and consequently to drug 
crystallization and growth of the large particles.  
Preparation of nanosuspension is simple and applicable 
to all drugs which are aqueous insoluble.  
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ABSTRACT:  
Nanosuspension contains submicron colloidal dispersion of pharmaceutical active ingredient particles in a liquid phase 
stabilized by surfactants. The poor water solubility of drugs is major problem for drug formulation. The reduction of drug 
particles into the sub-micron range leads to a significant increase in the dissolution rate, bioavailability as well as improve 
stability. Nanosuspension consists of the pure poorly water-soluble drug without any matrix material suspended in dispersion. 
Nanosuspension many attempts have been made to deliver poorly water soluble drugs as a nanosuspension prepared by 
adopting various methods. Techniques such as media milling and high pressure homogenization have been used commercially 
for producing nanosuspension. Recently, engineering of nanosuspension employs emulsions and microemulsion as templates. 
The unique features of nanosuspension have enabled their use in various dosage forms, including specialized delivery systems 
such as mucoadhesive hydrogels, parenteral, peroral, ocular and pulmonary routes.  
Keywords: Nanosuspension, Solubility enhancement, Saturation solubility, Homogenization. 
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Various formulation parameters that play a crucial role in 
the successful formulation of drugs are aqueous 
solubility, stability at ambient temperature and humidity, 
photo stability, compatibility with solvent and excipient. 
More than 40% of the new chemical entities being 
generated through drug discovery programmers are 
poorly water‐soluble or lipophilic compounds. The 
formulation of nano‐sized particles can be implemented 
to all drug compounds belonging to biopharmaceutical 
classification system (BCS) classes II, III and IV to 
increase their solubility and hence partition into 
gastrointestinal barrier. Nanosuspension is favored for 
compounds that are insoluble in water (but are soluble in 
oil) with high log P value, high melting point and high 
doses. Nanosuspension technology can also be used for 
drugs which are insoluble in both water and organic 
solvents.
4
  Nanosuspensions contain a pure poorly water 
soluble drug of nano size range (1-1000nm) in 
dispersion. Nanosuspension is submicron colloidal 
dispersion of pure particles of drug stabilized by 
surfactants. Nanosuspension consists of pure poorly 
water soluble drug without any matrix material 
suspended in dispersion.
5
 
The major advantages of nanosuspension technology are: 
6
 
 Oral administration of nanosuspensions provide 
rapid onset, reduced fed/fasted ratio and improved 
bioavailability.  
 Rapid dissolution and tissue targeting can be 
achieved by IV route of administration.  
 Reduced tissue irritation in case of 
subcutaneous/intramuscular administration.  
 Higher bioavailability and more consistent dosing in 
case of ocular administration and inhalation 
delivery.  
 Drugs with high log P value can be formulated as 
nanosuspensions to increase the bioavailability of 
such drugs.  
 Improvement in biological performance due to high 
dissolution rate and saturation solubility of the drug.  
 Long term physical stability.  
 Nanosuspensions can be incorporated in tablets, 
pellets, hydrogels and suppositories are suitable for 
various routes of administration. 
  
Attributes: 
 
Interesting special features of nanosuspensions are: 
7
 
 Increase in saturation solubility and consequently 
an increase in the dissolution rate of the drug.  
 Increase in adhesive nature, thus resulting in 
enhanced bioavailability.  
 Increasing the amorphous fraction in the particles, 
leading to a potential change in the crystalline 
structure and higher solubility.  
 Absence of Ostwald ripening, producing physical 
long term stability as an aqueous suspension.  
 Possibility of surface-modification of 
nanosuspension for site specific delivery.  
WHEN TO GO FOR NANO SUSPENSIONS 
APPROACH 
Preparing nano suspensions is preferred for the 
compounds that are insoluble in water (but are soluble 
in oil) with high log P value. Conventionally the drugs 
that are insoluble in water but soluble in oil phase 
system are formulated in liposome, emulsion systems 
but these lipidic formulation approaches are not 
applicable to all drugs. In these cases nano suspensions 
are preferred. In case of drugs that are insoluble in both 
water and in organic media instead of using lipidic 
systems nano suspensions are used as a formulation 
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approach. Nanosuspension formulation approach is 
most suitable for the compounds with high log P value, 
high melting point and high dose. 
8
 
PROPERTIES OF NANO SUSPENSIONS 
8,9
 
1. Physical Long-Term Stability: 
Nanosuspension is a highly dispersed system; therefore, 
physical instability due to Ostwald ripening would be 
expected. According to the Ostwald Freundlich 
equation, the saturation solubility increases with 
decreasing particle size. However, this effect is only 
pronounced for particles below approximately 2 ìm, 
especially below 1 ìm. It does not occur for powders of 
size normally processed in pharmacy. 
2. Saturation Solubility of Nanosuspension: 
Dissolution of drug is increased due to increase in the 
surface area of the drug particles from micrometers to 
the nanometer size. According to Noyes-Whitney 
equation (equation no.1) dissolution velocity increase 
due to increase in the surface area from micron size ton 
particles of nanometer size, 
Dx/dt = [(D x A/ h)] [Cs-X/V] ------------ (1) 
Where D is diffusion coefficient, A is surface area of 
particle, dx/dt is the dissolution velocity, V is volume of 
dissolution medium and X is the concentration in 
surrounding liquid. 
According to the Prandtl equation, for small particles 
the diffusional distance h decreases with decreasing 
particle size. The decrease in h increases Cs (saturation 
solubility) and leads to an increase in gradient (Cs-
Cx)/h and thus to an increase in the dissolution velocity. 
According to Ostwald-Freundlich equation decrease in 
particle size below 1ìm increases the intrinsic solubility 
or saturation solubility. 
10
 
3. Internal structure of Nanosuspension: 
The high-energy input during disintegration process 
causes structural changes inside the drug particles. 
When the drug particles are exposed to high-pressure 
homogenization particles are transformed from 
crystalline state to amorphous state. The change in state 
depends upon the hardness of drug, number of 
homogenization cycles chemical nature of drug and 
power density applied by homogenizer. 
11,12
 
Increasing dissolution rate through nanosuspension 
— theoretical aspects 6,7,8 
The increased saturation solubility and the accelerated 
dissolution velocity are the most important 
differentiating features of drug nanocrystals. In general, 
the saturation solubility (Cs) is defined as a drug-
specific constant depending only on the solvent and the 
temperature. This definition is only valid for drug 
particles with a minimum particle size in the 
micrometer range. A particle size reduction down to the 
nanometer range can increase the drug solubility. The 
solid API dissolution rate is proportional to the surface 
area available for dissolution as described by the 
Nernst–Brunner/Noyes–Whitney equation: 
 
Where, dX/dt=dissolution rate, Xd=amount dissolved, 
A=particle surface area, D=diffusion coefficient, 
V=volume of fluid available for dissolution, 
Cs=saturation solubility, h=effective m=boundary layer 
thickness. 
Based on this principle, API micronization has been 
extensively used in the pharmaceutical industry to 
improve oral bioavailability of drug compounds. It is 
evident that a further decrease of the particle size down 
to the sub-micron range will further increase dissolution 
rate due to the increase of the effective particle surface 
area 
9
. For example in the case of aprepitant, the 
nanocrystals dispersion of 120-nm particle size exhibits 
a 41.5-fold increase in surface area over the standard 5 
μm suspension 10. Furthermore, as described by the 
Prandtl equation, the diffusion layer thickness (h) will 
also be decreased thus resulting in an even faster 
dissolution rate 
11
. In addition to the dissolution rate 
enhancement described above, an increase in the 
saturation solubility of the nanosized API is also 
expected
 12
, as described by the Freundlich– Ostwald 
equation: 
 
where S=saturation solubility of the nanosized API, 
S8=saturation solubility of an infinitely large API 
crystal, ϒ is the crystal-medium interfacial tension, M is 
the compound molecular weight, r is the particle radius, 
ρ is the density, R is a gas constant and T is the 
temperature. 
Assuming a molecular weight of 500=1 g/ml and a. 
value of 15–20 mn m-1 for the crystal-intestinal fluid 
interfacial tension, the above equation would predict an 
approximately 10–15% increase in solubility at a 
particle size of 100 nm. However a more significant 
increase in solubility appears to occur in reality e.g. 
Muller and Peters reported an increase of 50% in the 
solubility of an insoluble antimicrobial compound when 
the particle size was reduced from 2.4 μm to 800 or 300 
nm 
12
. This increase in solubility leads to a further 
increase in dissolution rate and, as a result, 
nanosuspension often achieve significantly higher 
exposure levels compared to suspensions of micronized 
API, even when the same surfactants are used. Finally, 
the increase in surface wetting by the surfactants in the 
nanosuspension formulations most likely results in a 
further enhancement of the dissolution rates compared 
to micronized suspensions. 
EFFECT OF FORMULATION COMPONENTS 
ON PHYSICO-CHEMICAL 
CHARACTERERISTICS 
1) Stabilizer13,14,15 
Nanosuspension often employs stabilizers in order to 
prevent the phenomena of Ostwald ripening as 
discussed previously. In the absence of a suitable 
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stabilizer, the high surface energy of the particles in the 
nano-range can aggregate to form larger particles, 
thereby rendering the formulation unstable. The main 
function of the stabilizer is to wet the drug particle 
completely in order to inhibit agglomeration with 
another particle. It provides stearic or ionic barriers by 
way of which inter-particulate interactions in the 
nanosuspension are prevented. However, the 
concentration of the stabilizer in the nanosuspension 
must be optimum. Ideally, the drug-to-stabilizer ratio 
might vary 1:20 to 20:1. Various stabilizers have been 
investigated for their use in nanosuspension including 
cellulosic, poloxamers, polysorbates, lecithin and 
povidones. PVA of varying grades has been found to be 
a very effective stabilizer for nanosuspension produced 
by various methods. 
Effect on Physicochemical Characteristics
 13
 
PVA or Polyvinyl Alcohol has both hydrophobic and 
hydrophilic parts like acetate and hydroxyl groups 
respectively. These help in getting absorbed and 
oriented at the interface. In fact, the effectiveness of 
PVA in reducing the interfacial tension is such that it 
even promotes to maintaining low particle size of the 
nanoparticles in the nanosuspension. Even surfactants 
like Poloxamer and Tween 80 have been utilized for 
reducing the interfacial tension at the surface of the 
nanoparticles in the nanosuspension. 
2) Organic solvents:
 13,14,15]
 
Organic solvents are often employed in the formulation 
of nanosuspension by a variety of techniques.  
Effect on Physicochemical Characteristics 
One of the most important things to be kept in mind 
while utilizing organic solvents is their miscibility with 
water. The more the solvent is miscible and readily 
diffusible with water, the more effective will be the 
formation of nanoparticles. 
3) Co-surfactants
 13,14,15
 
Employing co-surfactants becomes important when 
nanosuspension is formulated from micro emulsion. Co-
surfactants influence phase behavior significantly and 
various solubilizers such as Transcutol, Glycofurol, 
Ethanol, and Isopropanol can be used as co-surfactants 
in the formulation of microemulsion. 
4) Other additives
 13,14,15
 
It might be so that a number of other additives are 
employed in the nanosuspension like osmogent, 
cryoprotectant or buffers depending upon the route of 
administration or to enhance the inherent properties of 
the drug. 
5) Temperature
 13,14,15
 
Maintaining optimum temperature conditions while 
carrying out the formulation of nanosuspension is 
important. Optimally it is very important to carry out 
the formulation at low temperature conditions while 
carrying out homogenization. For nanosuspension 
manufactured using the emulsion technique, it is 
significant that when the drug loaded organic solvent is 
added to the aqueous surfactant solution, 
homogenization is carried out in an ice bath or other 
provisions are made for lowering the temperature. The 
reason behind this is that since organic solvents are 
involved in the formulation, keeping a higher 
temperature will lead to rapid removal of the solvent 
from the system leading to formation of irregular 
particles. On the other hand in low temperature 
conditions, the solvent diffuses slowly out of the system 
leading to the formation of spherical and complete 
nanoparticles. 
6) Stirring Speed
14,15
 
Stirring speed is also an important formulation variable. 
The homogenization of nanosuspension leads to 
maintenance of low particle size and this is achieved 
either through High Pressure Homogenization (HPH) or 
High Shear Homogenization (HSH). It has been 
observed that on an average, increasing the speed of 
stirring during HSH or increasing the number of cycles 
during HPH leads to a reduction in the particle size 
towards the nano-sized range. However, it has been 
noted that operating the instruments at high speed 
conditions are not always optimum and an average 
speed has to be maintained. Optimally, for HSH 20000 
RPM and for HSH around 5 to 6 cycles have been 
recommended. This is because higher agitation speeds 
often lead to formation of a huge amount of foam in the 
suspension which often leads to early separation of the 
solid nanoparticles from the aqueous medium. As a 
result, this can lead to ineffective size reduction and 
insufficient formation of the nanoparticles. 
Post-production processing
 16,17,18,19
 
Post-production processing of nanosuspension becomes 
essential when the drug candidate is highly susceptible 
to hydrolytic cleavage or chemical degradation. 
Processing may also be required when the best possible 
stabilizer is not able to stabilize the nanosuspension for 
a longer period of time or there are acceptability 
restrictions with respect to the desired route. 
Considering these aspects, techniques such as 
lyophillization or spray drying may be employed to 
produce a dry powder of nano-sized drug particles. 
Rational selection has to be made in these unit 
operations considering the drug properties and 
economic aspects. Generally, spray drying is more 
economical and convenient than lyophillization. The 
effect of post-production processing on the particle size 
of the nanosuspension and moisture content of dried 
Nanosized drug should be given due consideration.
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Table 1: Various formulation excipients along with their functions: 
7
 
Excipient Function Example 
Stabilizers Wet the drug particles thoroughly, prevent -
Ostwald‟s ripening and agglomeration of 
nanosuspension, providing steric or ionic barrier. 
Lecithin, Poloxamer, Polysorbate, Cellulosic, 
Povidones 
Co-
surfactants 
Influence phase behavior when micro -emulsions are 
used to formulate nanosuspension. 
Bile salts, Dipotassium Glycerrhizinate, 
Transcutol, Glycofurol, Ethanol, Isopropanol. 
Organic 
solvent 
Pharmaceutically acceptable less hazardous -solvent 
for preparation of formulation. 
Methanol, Ethanol, Chloroform, Isopropanol, 
Ethyl acetate, Ethyl format, Butyl lactate, 
Triacetin, Propylene carbonate. 
Other 
additives 
According to the requirement of the route of -
administration or the properties of the drug moiety. 
Buffers, Salts, Polyols,osmogens, 
Cryoprotectant.. 
 
Table 2: Advantages of nanosuspension over conventional formulations:
 20,21,22
 
Route of 
administration 
Disadvantages of conventional 
formulations 
Benefits of nanosuspension 
Oral Slow onset of action/ poor absorption Rapid onset of action/ improved solubility so 
improved bioavailability 
Ocular Lacrimal wash off/ low bioavailability Higher bioavailability/ dose consistency 
Intravenous Poor dissolution/ non-specific action Rapid dissolution/ tissue targeting 
Intramuscular Low patient compliance due to pain Reduced tissue irritation 
Inhalations Low bioavailability due to low solubility Rapid dissolution/ high bioavailability/ dose 
regulation 
 
PREPARATION OF NANOSUSPENSION  
There are two methods for preparation of 
nanosuspension namely „Bottom up technology‟ and 
„Top down technology‟.  In Bottom up technology the 
drug is dissolved in a solvent, which is then added to 
non‐solvent that causes precipitation of the fine drug 
particles. All‐Trans retinoic acid nanosuspension was 
prepared with a precipitation method. Use of simple and 
low cost equipment and also benefit for higher 
saturation solubility is the advantage for precipitation 
technique compared to other methods of 
nanosuspension preparation. Precipitation technique is 
not applicable to drugs which are poorly soluble in 
aqueous and non aqueous media. In this technique, the 
drug needs to be soluble in at least one solvent which is 
miscible with nonsolvent. The major challenge is to 
avoid crystal growth due to Ostwald ripening being 
caused by different saturation solubility‟s in the vicinity 
of differently sized particles. The top down 
technologies include (a) media milling (b) high pressure 
homogenization (c) emulsion diffusion method (d) 
supercritical fluid method and these are preferred over 
the precipitation methods. 
23 
 
 
Figure 1: Flow Chart Showing Various Preparations Method
23
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A) Milling techniques: 
24,25,26,27,28
 
Media milling (Nanocrystals)  
This method was developed by Liversidge. In this 
method the nanosuspension is produced using 
high‐shear media mills or pearl mills. It consists of a 
milling chamber, a milling shaft and a recirculation 
chamber. Milling medium is framed of glass, zirconium 
oxide or highly cross‐linked polystyrene resin. The 
milling chamber is charged with the milling media, 
water, drug and stabilizer, and the milling media or 
pearls are then rotated at a very high shear rate. All 
process is performed under controlled temperatures. 
The high energy and shear forces generated as a result 
of the impaction of the milling media with the drug 
provide the energy input to break the microparticulate 
drug into nano‐sized particles. A nanosuspension of 
Naproxen with a mean particle size of 300‐600 nm was 
prepared using pearl milling technique.
 24,25,26,27,28
 
 
Figure 2: Schematic representation of Media milling process
 25
 
 
Advantages: 
24,25,26,27,28
 
 Drugs that are poorly soluble in both aqueous and 
organic media can be easily formulated into 
nanosuspension.  
 Ease of scale-up and little batch-to-batch variation.  
 Narrow size distribution of the final nano-sized 
product.  
 Flexibility in handling the drug quantity, ranging 
from 1 to 400mgmL-1, enabling formulation of 
very dilute as well as highly concentrated 
nanosuspension.  
Disadvantages: 
24,25,26,27,28
 
The major concern is the generation of residues of 
milling media, which may be introduced in the final 
product as a result of erosion .This could be problematic 
when nanosuspension is intended to be administered for 
a chronic therapy. The severity of this problem has been 
reduced to a great extent with the advent of polystyrene 
resin-based milling medium. 
Dry Co-grinding
24,25,26,27,28
  
Preparing stable nanosuspension using poorly soluble 
drugs with soluble polymers and copolymers after 
dispersing in a liquid media has been reported. The 
colloidal particles formation of many poorly water 
soluble drugs; griseofulvin, glibenclamide and 
nifedipine obtained by grinding with 
polyvinylpyrrolidone (PVP) and sodium dodecylsulfate 
(SDS). Many soluble polymers and co-polymers such as 
PVP, polyethylene glycol (PEG), hydroxypropyl 
methylcellulose (HPMC) and cyclodextrin derivatives 
have been used. Physicochemical properties improved 
because of an improvement in the surface polarity and 
transformation from a crystalline to an amorphous drug. 
It can be conducted without organic solvents. The co-
grinding technique can reduce particles to the 
submicron level and a stable amorphous solid can be 
obtained. 
24,25,26,27,28
 
High pressure homogenization 
(dissocubes/nanopure):  
Homogenization involves the forcing of the suspension 
under pressure through a valve having a narrow 
aperture. The most commonly used homogenizer in the 
preparation of nanosuspension is the APV micron LAB 
40(APV Deutschland GmbH, Lubeck, Germany). 
However, other piston‐gap homogenizers from Avestin 
(Avestin Inc., Ottawa, Canada) and Stansted (Stansted 
Fluid Power Ltd, Stansted, UK) can also be used. The 
instrument can be operated at pressures varying from 
100 to 1500 bars. In some instruments, a maximum 
pressure of 2000 bars can be reached.
 24,25,26,27,28
 
Principle:  
During homogenization, the fracture of drug particles is 
brought about by cavitation, high-shear forces and the 
collision of the particles against each other. The drug 
suspension, contained in a cylinder of diameter about 3 
mm, passes suddenly through a very narrow 
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homogenization gap of 25μm, which leads to a high 
streaming velocity. In the homogenization gap, 
according to Bernoulli‟s equation, the dynamic pressure 
of the fluid increases with the simultaneous decrease in 
static pressure below the boiling point of water at room 
temperature. In consequence, water starts boiling at 
room temperature, leading to the formation of gas 
bubbles, which implode when the suspension leaves the 
gap (called cavitation) and normal air pressure is 
reached again. The implosion forces are sufficiently 
high to break down the drug microparticles into 
nanoparticles. Additionally, the collision of the particles 
at high speed helps to achieve the nano-sizing of the 
drug.
 [24,25,26,27,28]
 A high pressure homogenizer consists 
of a high pressure plunger pump with a subsequent 
relief valve with fixed valve seat and an adjustable 
valve. These parts form and adjustable radial precision 
gap. It is advisable to start with micronized drug 
particles (<25μm)for production of nanosuspension in 
order to prevent blocking of homogenization gap. 
Before subjecting the drug to the homogenization 
process, it is essential to form a presuspension of the 
micronized drug in a surfactant solution using 
high‐speed stirrers. Hence generally a jet milled drug is 
employed as the starting material for producing 
dissocubes. Homogenization can be performed in 
water(dissocubes)or alternatively in nonaqueous 
media(nanopure). Most of the cases require multiple 
passes or cycles through the homogenizer, which 
depends on the hardness of the drug, the desired mean 
particle size, and required homogeneity. High‐pressure 
homogenizers are available with different capacities 
ranging from 40ml (for laboratory purposes) to a few 
thousand litres (for large‐scale production). 24,25,26,27,28
 
 
Figure 3:Schematic representation of high pressure homogenization process
24,25,26,27,28
 
 
Advantages: 
24,25,26,27,28
 
 Drugs that are poorly soluble in both aqueous and 
organic media can be easily formulated into 
nanosuspensions.  
 Narrow size distribution of the nanoparticulate drug 
present in the final product.  
 Allows aseptic production of nanosuspensions for 
parenteral administration.  
Disadvantages: 
24,25,26,27,28
 
 Prerequisite of micronized drug particles. 
 Prerequisite of suspension formation using high-
speed mixers before subjecting it to homogenization.  
B) Combined precipitation and homogenization 
(Nanoedege):
 24,25,26,27,28
 
Principle involved is same that of the precipitation and 
homogenization techniques. This technique has an 
advantage of getting smaller particle size and greater 
stability in short period of time. In this technique the 
precipitated suspension is further homogenized to get 
smaller particle size and to avoid crystal growth. 
Precipitation is performed in water using water miscible 
solvent, such as methanol, ethanol, and isopropanol. It 
is desired to remove the solvent completely by 
including evaporation step to provide a solvent free 
modified starting material followed by high pressure 
homogenization. 
24,25,26,27,28
 
Nanojet technology 
24,25,26,27,28
 
It uses a chamber where a stream of suspension is 
divided into two or more parts, which colloid with each 
other at high pressure. The high shear force produced 
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during the process results in particle size reduction. 
Equipment using this principle includes the M110L and 
M110S microfluidizers (Microfluidics). Dearn prepared 
nanosuspensions of atovaquone using the 
microfluidization process. Major disadvantage of this 
technique is the high number of passes through the 
microfluidizer and that the product obtained contains a 
relatively larger fraction of microparticles. 
24,25,26,27,28
 
C) Emulsion solvent diffusion method:  
Apart from the use of emulsion as drug delivering 
vehicle they can also be used as templates to produce 
nanosuspension. The use of emulsions as templates is 
applicable for those drugs that are soluble in either 
volatile organic solvent or partially water‐miscible 
solvent. Such solvents can be used as the dispersed 
phase of the emulsion. An organic solvent or mixture of 
solvents loaded with the drug is dispersed in the 
aqueous phase containing suitable surfactants with 
stirring to form an emulsion. The obtained emulsion 
was further homogenized by high pressure 
homogenization. After homogenization cycles the 
emulsion was diluted with water, homogenized by 
homogenizer to diffuse the organic solvent and convert 
the droplets into solid particles. Control the particle size 
of the nanosuspension by controlling the size of the 
emulsion. Optimizing the surfactant composition 
increases the intake of organic phase and ultimately the 
drug loading in the emulsion. Originally methanol, 
ethanol, ethyl acetate, chloroform are used as organic 
solvents. 
24,25,26,27,28
 
Advantages:
 24,25,26,27,28
 
 Use of specialized equipment is not necessary.  
 Particle size can easily be controlled by controlling 
the size of the emulsion droplet.  
 Ease of scale-up if formulation is optimized 
properly.  
Disadvantages: 
24,25,26,27,28
 
 Drugs that are poorly soluble in both aqueous and 
organic media cannot be formulated by this 
technique.  
 Safety concerns because of the use of hazardous 
solvents in the process.  
 Need for diultrafiltration for purification of the 
drug nanosuspension, which may render the 
process costly.  
 High amount of surfactant/stabilizer is required as 
compared to the production techniques described 
earlier.  
 It applied to the poorly water-soluble and poorly 
bioavailable anti-cancer drug mitotane, where a 
significant improvement in the dissolution rate of 
the drug (five-fold increase) as compared to the 
commercial product was observed.  
Microemulsions as templates 
24,25,26,27,28
 
Microemulsions are thermodynamically stable and 
isotropically clear dispersions of two immiscible 
liquids, such as oil and water, stabilized by an 
interfacial film of surfactant and co-surfactant.Their 
advantages, such as high drug solubilization, long shelf-
life and ease of manufacture, make them an ideal drug 
delivery vehicle. Recently, the use of microemulsions as 
templates for the production of solid lipid nanoparticles 
and polymeric nanoparticles  has been described. The 
internal phase of these microemulsions could be either a 
partially miscible liquid or a suitable organic solvent. 
The drug can be either loaded in the internal phase or 
pre-formed microemulsions can be saturated with the 
drug by intimate mixing. The influence of the amount 
and ratio of surfactant to co-surfactant on the uptake of 
internal phase and on the globule size of the 
microemulsion should be investigated and optimized in 
order to achieve the desired drug loading .The 
advantages and disadvantages are the same as for 
emulsion templates. The only added advantage is the 
need for less energy input for the production of 
nanosuspensions by virtue of microemulsions. The 
production of drug nanosuspensions using 
microemulsions as templates has been successfully 
applied to the poorly water-soluble and poorly 
bioavailable antifungal drug griseofulvin, where a 
significant improvement in the dissolution rate of the 
drug (three-fold increase) as compared to the 
commercial product was observed. 
Melt emulsification method 
24,25,26,27,28
 
Drug is dispersed in the aqueous solution of stabilizer 
and heated above the melting point of the drug and 
homogenized to give an emulsion. During this process, 
the sample holder was enwrapped with a heating tape 
fitted with temperature controller and the temperature of 
emulsion was maintained above the melting point of the 
drug. The emulsion was then cooled down either slowly 
to room temperature or on an ice‐bath. The main 
advantage is total avoidance of organic solvents during 
the production process. Nanosuspension of ibuprofen 
was prepared by this method. This method show greater 
dissolution rate than formulating by solvent diffusion 
method.  
Supercritical fluid method: 
24,25,26,27,28
 
Supercritical fluid technology can be used to produce 
nanoparticles from drug solutions. The various methods 
attempted are rapid expansion of supercritical solution 
process (RESS), supercritical anti-solvent process and 
precipitation with compressed anti-solvent process 
(PCA).The RESS involves expansion of the drug 
solution in supercritical fluid through a nozzle, which 
leads to loss of solvent power of the supercritical fluid 
resulting in precipitation of the drug as fine particles. In 
the PCA method, the drug solution is atomized into a 
chamber containing compressed CO2. As the solvent is 
removed, the solution gets supersaturated and thus 
precipitates as fine crystals. The supercritical anti- 
solvent process uses a supercritical fluid in which a 
drug is poorly soluble and a solvent for the drug that is 
also miscible with the supercritical fluid.  
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Disadvantages: 
24,25,26,27,28
 
 Hazardous solvents and use of high proportions of 
surfactants and stabilizers as compared with other 
techniques  
 Particle nucleation overgrowth due to transient high 
super saturation.  
CHARACTERIZATION OF NANOSUSPENSION 
[24,25,26,27,28]
 
According to Muller‟s review, the necessity 
characterization parameters for nanosuspensions are 
size and size distribution, particle charge (zeta 
potential), crystalline status, as well as dissolution 
velocity and saturation solubility.  
 
 
Figure 4: Flowchart showing various methods for characterization of nanosuspensions
24,25,26,27,28
 
 
Particle size distribution: 
24,25,26,27,28
 
The most important characterization parameter, also 
called Polydispersity Index which governs the 
physicochemical properties like saturation solubility, 
dissolution velocity, physical stability and even 
biological performance.  Different methods for 
determining particle size distribution are photon 
correlation spectroscopy (PCS), laser diffraction (LD), 
and coulter counter multisizer.  
 PCS can even be used for determining the width of 
the particle size distribution. PCS determines the 
particle size in the range of (3nm to 3 μm).  
 The PI is an important parameter that governs the 
physical stability of nanosuspensions and should be 
as low as possible for the long term stability of 
nanosuspensions.  
a) A PI value of 0.1–0.25 indicates a fairly narrow size 
distribution  
b) PI value greater than 0.5 indicates a very broad 
distribution.  
c) Laser diffractometry (LD) analysis detect and 
quantify the drug microparticles that might have been 
generated during the production process. LD determines 
the particle size in the range of 0.05-80μm upto 
2000μm. The typical LD characterization includes 
determination of diameter 50% LD (50) and diameter 
99% LD (99) values, which indicate that either 50 or 
99% of the particles are below the indicated size.  
For parental use the particle size should be less than 
5μm, considering that the smaller size of the capillaries 
is 5‐6μm and hence a higher particle size can lead to 
capillary blockade and embolism.  
Particle charge (zeta potential):
 24,25,26,27,28
  
The physical stability of a nanosuspension is governed 
by the particle charge (zeta potential) is effected by the 
stabilizer and the drug itself.  
 For electrostatically stabilized nanosuspension a 
minimum zeta potential of ±30mv is required.  
 For combined steric and electrostatic stabilized 
nanosuspensions a minimum of ±20mv is required.  
Crystalline state and particle morphology: 
24,25,26,27,28
 
It is important to know the crystal morphology of the 
drug in the nanosuspension. Polymorphic or 
morphological changes in drug that occur during 
nanosizing can be determined by the knowledge of 
crystalline state and particle morphology. Amorphous 
state of the drug formed during preparation of 
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nanosuspension is determined by X-ray diffraction 
analysis. It gives information about the changes in the 
physical state of the drug particles as well as the extent 
of the amorphous fraction. Differential scanning 
calorimetry can be used additionally. Scanning electron 
microscopy is also used to get exact information about 
particle morphology. Effect of high pressure 
homogenization on the crystalline structure of the drug 
is estimated by X‐ray diffraction analysis in 
combination with differential scanning calorimetry. 
Techniques like scanning electron microscopy (SEM), 
atomic force microscopy (AFM) or transmission 
electron microscopy (TEM) are preferred for 
determining the exact size and morphology of 
nanoparticles in suspension.  
Saturation solubility and dissolution velocity:
 
24,25,26,27,28
 
Nanosuspensions can increase the dissolution velocity 
as well as the saturation solubility. The saturation 
solubility of the drug in different physiological buffers 
as well as at different temperatures. The assessment of 
saturation solubility and dissolution velocity helps in 
determining the in vitro behaviour of the formulation. 
In-Vivo Pharmacokinetic correlation: 
24,25,26,27,28
 
For intravenously injected nanosuspensions, the organ 
distribution in part depends on the nanoparticle size and 
surface property. Surface hydrophilicity/hydrophobicity 
and interactions with plasma proteins are considered as 
important factors affecting the in-vivo organ distribution 
behaviour after i.v. injection of nanosuspensions. 2-D 
PAGE can be employed for the quantitative 
measurement of protein adsorption to nanoparticle 
surface after i.v. injection of drug nanosuspensions to 
animals. 
24,25,26,27,28
 
PREFERRED DOSAGE FORMS OF 
NANOSUSPENSIONS 
24,25,26,27,28
 
Aqueous or non-aqueous drug nanosuspensions 
exhibiting a physical long-term stability should be 
sufficient to place them on the market as liquid 
products. In the case of drug nanosuspensions in pure 
water or in water containing mixtures, they can be used 
as granulation fluid in the granulation process for the 
production of tablets or alternatively as wetting agents 
for the extrusion mass to produce pellets. Spray-drying 
of the nanosuspension is also possible. The produced 
powders can then be used again for tablet or pellet 
production or alternatively be filled in hard gelatin or 
HPMC capsules. The drug nanocrystals produced in 
non-aqueous media such as oils or liquid/solid PEG can 
be used directly for filling in capsules. Production of 
drug nanosuspensions in melted PEG which is solid at 
room temperature opens further perspectives. Direct 
filling of capsules with the hot nanosuspension is 
possible.
35
 Alternatively after solidification of the PEG, 
the drug nanocrystal containing mass can be ground and 
filled as a powder into the capsules. To summarize, 
there are different ways to transfer the drug 
nanocrystals to a final dry oral dosage form for the 
patient.  
APPLICATION OF NANOSUSPENSIONS 
24,25,26,27,28
 
1 Parenteral administration 
Advantages 
Liposomes are much more tolerable and versatile in 
terms of parenteral delivery. However, they often suffer 
from problems such as physical instability, high 
manufacturing cost and difficulties in scale-up. 
Nanosuspensions would be able to solve the problems 
mentioned above. In addition, nanosuspensions have 
been found to increase the efficacy of parenterally 
administered drugs. For administration by the parenteral 
route, the drug either has to be solubilized or has 
particle/globule size below 5 μm to avoid capillary 
blockage. The current approaches for parenteral 
delivery include salt formation, solubilization using co-
solvents, micellar solutions, complexation with 
cyclodextrin and recently liposomes. 
2 Peroral administrations 
Advantages 
Nanosizing of drugs can lead to a dramatic increase in 
their oral absorption and subsequent bioavailability. 
Improved bioavailability can be explained by the 
adhesiveness of drug nanoparticles to the mucosa, the 
increased saturation solubility leading to an increased 
concentration gradient between gastrointestinal tract 
lumen and blood and the increased dissolution velocity 
of the drug. Aqueous nanosuspensions can be used 
directly in a liquid dosage form and a dry dosage form 
such as tablet or hard gelatin capsule with pellets. 
3 Pulmonary drug delivery 
Advantages 
Aqueous nanosuspensions can be nebulized using 
mechanical or ultrasonic nebulizers for lung delivery. 
Basically the nanosuspensions can be used in all 
nebulizers. The dispersions can be relatively high 
concentrated. Due to the presence of many small 
particles instead of a few large microparticles, all 
aerosol droplets are likely to contain drug nanoparticles. 
4 Target drug delivery 
Advantages 
Nanosuspensions can also be used for targeted delivery 
as their surface properties and in vivo behavior can 
easily be altered by changing either the stabilizer or the 
milieu. Their versatility, ease of scale up and 
commercial product enable the development of 
commercial viable nanosuspensions for targeted 
delivery. The engineering of stealth nanosuspensions by 
using various surface coatings for active or passive 
targeting of the desired site is the future of targeted drug 
delivery systems. 
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Table 1: Current marketed formulations using nanosuspension technology: 
1. 38  Aphidicolin  To improve drug targeting effect against Leshmania infected 
macrophages  
Kayser .O [60]  
2. 39  Cloricromene  To improve stability of the drug and its availability at the ocular 
level.  
Rosario P et al [61]  
3. 40  Buparvaquone  To enhance effectiveness if the drug in the treatment of 
Pneumocystis pneumonia. (pulmonary)  
Norma H-K et al [62]  
4. 41  Retinoic acid  To attain controlled release and high saturation solubility of the 
drug  
Zhang.X et al [63]  
5. 42  1,3-dicyclohexyl 
urea  
To maintain DCU free plasma levels above the soluble epoxide 
hydrolase inhibitor. (oral I.V bolus & I.V infusion dosing)  
Jan L.W et al [64]  
6. 43  Risperidone  To treat Psychotic disorders. (parenteral)  Muthu M.S et al [65]  
7. 44  Acyclovir  For prolonged release of drug & to increase bioavailability. 
(ocular)  
Panchaxari D et al [66]  
8. 45  Atorvastatin  To enhance solubility of the drug  Arunkumar N et al [67]  
9. 46  Hesperetin  To enhance the effect of drug through dermal delivery  Prabhat R.M et al [68]  
10. 47  Meloxicam  To enhance the dissolution of the drug. (oral)  Ambrus.R et al [69]  
11. 48  Itraconazole  To increase aqueous solubility & dissolution & hence to increase 
oral bioavailability. (aerosols)  
Shivanandh P et al [70]  
12. 49  Forskolin  To enhance antiglaucoma efficacy. (ocular)  Saurabh G et al [71]  
13. 50  Silyben  Increase in bioavailability and sustained drug release drug profile 
is observed. (oral & I.V)  
Yancci W et al [72]  
14. 51  Miconazole  To increase bioavailability  Ana M.C et al [73]  
15. 52  Diclofenac  To enhance solubility of the drug. (intramuscular)  Amit R P et al [74]  
16. 53  Simvastatin  To enhance dissolution of the drug compared to suspension  Vikram.M.P et al [75]  
17. 54  Famotidine  To improve dissolution rate of the drug. (mucoadhesive)  Dhaval J.P et al [76]  
 
7. CONCLUSION 
The nanosuspensions technology can be successfully 
utilized for overcoming problems associated with 
poorly soluble drugs or lipophilic drugs insoluble in 
both organic and aqueous media. Large scale 
production methods of production of nanosuspensions 
like media milling or high pressure homogenization 
have been employed for manufacture. There exist a 
number of patented technologies which have a huge 
commercial application and can be utilized for further 
advancements in the area of formulation of poorly 
soluble drugs. The recent advancements in the work 
being done related to nanosuspensions show that many 
formulations are being developed on a laboratory scale 
which have a potentially important clinical significance 
and can be used for the mitigation of diseases. 
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